Cannabidiol for Treating PTSD symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid with TBI: A Placebo-controlled RCT with Neural-circuit centered Precision Medicine Prediction of Response.

Go Back to All Clinical Trials

Cannabidiol for Treating PTSD symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid with TBI: A Placebo-controlled RCT with Neural-circuit centered Precision Medicine Prediction of Response.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Traumatic Brain Injury
Post Traumatic Stress Disorder
Age: Between 18 Year(s) - 85 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. DSM-5 current diagnosis of PTSD with the Clinician Administered PTSD Scale (CAPS-5)
2. TBI present (for PTSD+TBI subjects only)
3. Mild TBI (for PTSD+TBI subjects only)
4. Able to provide at least 2 locators (contacts)
5. Able to provide voluntary written informed consent
6. Participants who are reliably domiciled
7. Agreement to abstain from all other cannabinoid use for the duration of the study
8. Willingness to use contraception if male or female of childbearing potential.

You may not be eligible for this study if the following are true:

1. History of open head injury
2. TBI within the last 6 months
3. Moderate-severe TBI
4. SUD in the last 6 months other than mild AUD or nicotine use
5. Use of any cannabinoid containing product within the last 1 month
6. Positive urine drug screen
7. Currently prescribed medications with possible CBD-drug interactions
8. Exposure to trauma in the last 30 days, including police duty or military service
9. Psychotherapy for PTSD or other psychiatric conditions if initiated within 2 months of screening
10. Not stable for at least 2 months on psychiatric medication, anticonvulsants, antihypertensive medication, sympathomimetic medication, estrogen replacement therapy, medications associated with neurogenesis, or steroid medication
11. Active suicide attempt within the past year
12. Current significant suicidality (assessed using the C-SSRS), any significant suicidal behavior in the past 12 months
13. Neurologic disorder or systemic illness affecting CNS function (apart from TBI)
14. Major medical illness
15. Clinical diagnosis of anemia
16. Significant laboratory abnormalities
17. Significant allergic reactions to the drug including cannabinoids or sesame oil
18. Those pregnant or lactating
19. Contraindication to MRI
20. Males and females who plan to conceive a child during or two weeks following the study
21. Active legal problems likely to result in incarceration within 12 weeks of treatment initiation
22. Has a high risk of adverse emotional or behavioral reaction
23. Inpatient psych treatment in past 12 months
24. Active military

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies